Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin plus Exenatide in Obese T2DM
NCT03419624Phase 3Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by University Medical Center Hamburg-Eppendorf. Started Feb 2018; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03419624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419624.